Cambridge Cognition acquires Ivory

Cambridge Cognition has acquired Ivory, an India-based brain health platform, with the transaction terms remaining undisclosed. This acquisition involves a commercialisation agreement aimed at deploying Cambridge Cognition's 'CANTAB Pathway' digital cognitive assessment tool throughout healthcare and consumer health sectors across India. The move signals Cambridge Cognition's strategic entry into a rapidly expanding international market.

The collaboration will see CANTAB Pathway implemented in both professional healthcare settings and consumer markets through Ivory's established clinical network and consumer-facing platform. Rob Baker, CEO of Cambridge Cognition, emphasized India's potential as a major growth market due to its significant unmet need for cognitive impairment diagnosis. India is home to an estimated 138 million individuals over the age of 60, with research suggesting that up to 34 million of them could suffer from cognitive impairments, yet a staggering 90% of cases go undiagnosed.

For Cambridge Cognition, this acquisition signifies a strategic geographic expansion to leverage India's large and increasingly health-conscious population. The market opportunity is driven by India's burgeoning middle and affluent classes who are keen on longevity and high-quality healthcare solutions, coupled with a young, tech-savvy urban demographic proactive in health management. The partnership is expected to boost access to early-stage brain health assessment tools and address a crucial gap in the market that Ivory highlighted in its recent Brain Health Report.

The deployment plan for CANTAB Pathway will initially cover various languages including English, Hindi, Tamil, Telugu, Bengali, and Kannada, with plans for further linguistic diversification. This localization strategy is vital for penetrating the diverse Indian market. Ivory CEO Issac John noted that the collaboration is aligned with Ivory’s mission to transition from late-stage diagnoses towards early brain health interventions, building on CANTAB’s established scientific credibility.

Cambridge Cognition's share price reacted positively to the announcement, rising 11.39% to 44 pence. Moving forward, the success of this venture will likely depend on the efficient execution of the rollout and how well it meets the regulatory and market-specific challenges in such a vast and diverse market. As India lacks a definitive cure for neurodegenerative diseases, the focus on early detection and prevention becomes increasingly relevant, potentially setting a precedent for similar partnerships in other emerging economies.